Pharma BD Deal Intelligence
Johnson & Johnson agreed to acquire clinical-stage Ollin Biosciences for $2.2 billion in cash upfront, with up to approximately $1.125 billion in additional regulatory and commercial milestone payments. The acquisition brings OLN324, a Phase 3-stage investigational bispecific antibody targeting vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2), two pathways implicated in retinal vascular disease. OLN324 uses a minibody format with enhanced Ang2 potency, which J&J positions as offering improved retinal fluid control, more durable responses and longer intervals between intravitreal injections. Target indications are wet age-related macular degeneration and diabetic macular edema. Separately, Blackstone Life Sciences will pay Johnson & Johnson a total of $750 million over multiple years to fully fund Phase 3 development of OLN324. The transaction is expected to close before the end of 2026.
← Browse all deals · How we score deals
More: 2026 deals · Johnson & Johnson deals